43,700 Shares in Lifecore Biomedical, Inc. (NASDAQ:LFCR) Purchased by Rangeley Capital LLC

Rangeley Capital LLC acquired a new stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 43,700 shares of the company’s stock, valued at approximately $325,000. Rangeley Capital LLC owned 0.12% of Lifecore Biomedical as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the business. ARS Investment Partners LLC bought a new position in shares of Lifecore Biomedical in the fourth quarter valued at about $74,000. Prudential Financial Inc. acquired a new position in Lifecore Biomedical in the 4th quarter valued at about $95,000. Lepercq Multi Asset Fund bought a new position in Lifecore Biomedical in the 4th quarter valued at about $169,000. Public Employees Retirement System of Ohio acquired a new stake in Lifecore Biomedical during the third quarter worth approximately $119,000. Finally, Steward Partners Investment Advisory LLC lifted its position in Lifecore Biomedical by 61.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 27,184 shares of the company’s stock worth $202,000 after acquiring an additional 10,320 shares during the last quarter. 83.36% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Paul Josephs bought 17,000 shares of Lifecore Biomedical stock in a transaction dated Wednesday, January 8th. The shares were bought at an average cost of $5.74 per share, with a total value of $97,580.00. Following the acquisition, the chief executive officer now owns 559,717 shares in the company, valued at $3,212,775.58. This trade represents a 3.13 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 32.20% of the company’s stock.

Lifecore Biomedical Trading Up 2.4 %

Shares of Lifecore Biomedical stock opened at $7.20 on Thursday. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. The firm has a 50-day moving average of $6.18 and a 200-day moving average of $6.24. Lifecore Biomedical, Inc. has a 52-week low of $3.68 and a 52-week high of $7.99. The stock has a market cap of $266.58 million, a PE ratio of -12.86 and a beta of 0.96.

Lifecore Biomedical (NASDAQ:LFCR) last announced its earnings results on Thursday, January 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.02. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. As a group, sell-side analysts forecast that Lifecore Biomedical, Inc. will post -0.91 EPS for the current year.

Analyst Ratings Changes

Separately, Stephens reaffirmed an “equal weight” rating and issued a $6.00 target price on shares of Lifecore Biomedical in a research report on Friday, January 3rd.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.